Preliminary report of a toxicity study of hydroxyurea in sickle cell disease

被引:51
|
作者
de Montalembert, M
Bégué, P
Bernaudin, F
Thuret, I
Bachir, D
Micheau, M
机构
[1] Hop Necker Enfants Malad, F-75015 Paris, France
[2] Hop A Trousseau, F-75012 Paris, France
[3] Hop Intercommunal Creteil, Serv Pediat, F-94000 Creteil, France
[4] Hop Enfants La Timone, Serv Pediat & Hematol Pediat, F-13385 Marseille, France
[5] Hop Henri Mondor, Ctr Drepanocytose, F-94000 Creteil, France
[6] Serv Pediat B, F-33076 Bordeaux, France
关键词
sickle cell disease; pain; hydroxyurea;
D O I
10.1136/adc.81.5.437
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Aim-To evaluate the tolerance off hydroxyurea in children affected with sickle cell disease. Design-Questionnaire study of French physicians likely to treat patients with sickle cell disease. Data were collected on 101 children with sickle cell disease, treated for a median of 22 months, 36 of whom were treated for more than three years. 13 children were younger than 5 years of age at inclusion. Results-Hydroxyurea was I;topped for medical reasons in 11 patients: 6 failures, 1 pregnancy, 1 cutaneous rash; 1 leg ulcer, 1 lupus. Acute lymphoblastic leukaemia occurred in a girl treated for 1.5 months with hydroxyurea, this short interval arguing against a causative association. One 17 year old boy had paraparesis after 8 years of treatment. Conclusions-No major short or medium term toxicity was related to hydroxyurea in this cohort of 101 children. However, the number of children treated for more than 3 years is too few to make firm conclusions on the long term tolerance of this drug.
引用
收藏
页码:437 / 439
页数:3
相关论文
共 50 条
  • [1] Hydroxyurea to Treat Pediatric Sickle Cell Disease in Haiti a Preliminary Report
    McGregor, Nicholas
    Lerebours, Emmeline
    Bodas, Prasad
    [J]. BLOOD, 2016, 128 (22)
  • [2] Hydroxyurea in sickle cell disease
    Schechter, AN
    Rodgers, GP
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05): : 333 - 333
  • [3] Consent, compliance, toxicity and efficacy of hydroxyurea therapy in sickle cell disease
    Hilliard, LM
    Schwartz, J
    Collins, HC
    Howard, TH
    [J]. PEDIATRIC RESEARCH, 2003, 53 (04) : 277A - 277A
  • [4] Monitoring toxicity, impact, and adherence of hydroxyurea in children with sickle cell disease
    Brandow, Amanda M.
    Panepinto, Julie A.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (09) : 804 - 806
  • [5] Hydroxyurea for Sickle Cell Disease: A Systematic Review for Efficacy and Toxicity in Children
    Strouse, John J.
    Lanzkron, Sophie
    Beach, Mary Catherine
    Haywood, Carlton
    Park, Haeseong
    Witkop, Catherine
    Wilson, Renee F.
    Bass, Eric B.
    Segal, Jodi B.
    [J]. PEDIATRICS, 2008, 122 (06) : 1332 - 1342
  • [6] HYDROXYUREA FOR SICKLE-CELL DISEASE
    ROWE, PM
    [J]. LANCET, 1995, 345 (8945): : 311 - 311
  • [7] HYDROXYUREA AND SICKLE-CELL DISEASE
    ORRINGER, EP
    PARKER, JC
    [J]. HEMATOLOGIC PATHOLOGY, 1992, 6 (04) : 171 - 178
  • [8] Hydroxyurea for the treatment of sickle cell disease: Efficacy, barriers, toxicity, and management in children
    Strouse, John J.
    Heeney, Matthew M.
    [J]. PEDIATRIC BLOOD & CANCER, 2012, 59 (02) : 365 - 371
  • [9] Hydroxyurea (hydroxycarbamide) for sickle cell disease
    Rankine-Mullings, Angela E.
    Nevitt, Sarah J.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2022, (09):
  • [10] The role of hydroxyurea in sickle cell disease
    Halsey, C
    Roberts, IAG
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (02) : 177 - 186